<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386591</url>
  </required_header>
  <id_info>
    <org_study_id>Naloxone P1a-003</org_study_id>
    <nct_id>NCT03386591</nct_id>
  </id_info>
  <brief_title>Comparison of Naloxone Pharmacokinetics</brief_title>
  <official_title>Comparison of Naloxone Pharmacokinetics Using Marketed Naloxone Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intranasal (IN) naloxone administration is an effective alternative to intravenous (IV) or&#xD;
      intramuscular (IM) naloxone by emergency medical services for opioid overdoses and has been&#xD;
      used successfully for this purpose as reported in clinical observational studies and a&#xD;
      randomized controlled trial. Most of the published clinical studies concerning IN&#xD;
      administration used an improvised kit of 2 mg naloxone/2 mL saline and a mucosal atomizer&#xD;
      device (MAD), which is not FDA-approved for this indication. Pharmacokinetic (PK) data using&#xD;
      these kits is not available in the published literature. This study is designed to determine&#xD;
      the PK of naloxone following one and two IN administrations using the improvised kits&#xD;
      compared to 2 and 4 mg delivered IN using the FDA-approved Narcan nasal spray device and 2 mg&#xD;
      administered IM using the Evzio autoinjector.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Actual">March 6, 2018</completion_date>
  <primary_completion_date type="Actual">February 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be an inpatient open-label, randomized, 5-period, 5-treatment, 5-sequence, crossover study involving approximately 30 healthy subjects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of naloxone</measure>
    <time_frame>11 days</time_frame>
    <description>Maximum plasma concentration, time of maximum observed concentration and area under the concentration-time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>16 days</time_frame>
    <description>Number of participants with AEs, vital signs, ECG, laboratory changes and nasal irritation following the administration of naloxone.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Mucosal Atomization (1 administration)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucosal Atomization (2 administrations)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narcan 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Intranasal administration of 2 mg naloxone using Narcan nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narcan 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Intranasal administration of 4 mg naloxone using Narcan nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular auto injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Intramuscular administration of 2 mg naloxone using Evzio auto-injector</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Comparing pharmacokinetics of naloxone</description>
    <arm_group_label>Intramuscular auto injector</arm_group_label>
    <arm_group_label>Mucosal Atomization (1 administration)</arm_group_label>
    <arm_group_label>Mucosal Atomization (2 administrations)</arm_group_label>
    <arm_group_label>Narcan 2mg</arm_group_label>
    <arm_group_label>Narcan 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mucosal atomization device and syringe</intervention_name>
    <description>Injection</description>
    <arm_group_label>Mucosal Atomization (1 administration)</arm_group_label>
    <arm_group_label>Mucosal Atomization (2 administrations)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Narcan</intervention_name>
    <description>Nasal Spray</description>
    <arm_group_label>Narcan 2mg</arm_group_label>
    <arm_group_label>Narcan 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intramuscular Auto Injector</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Intramuscular auto injector</arm_group_label>
    <other_name>Evzio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females 18 to 55 years of age, inclusive&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  BMI ranging from 18 to 32 kg/m2, inclusive&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
          -  No clinically significant concurrent medical conditions determined by medical history,&#xD;
             physical examination, clinical laboratory examination, vital signs, and 12-lead ECG&#xD;
&#xD;
          -  Male subjects must agree to use an acceptable method of contraception with female&#xD;
             partners as well as not to donate sperm from the screening visit until 90 days after&#xD;
             the last study drug administration&#xD;
&#xD;
          -  Female subjects of childbearing potential must agree to use an acceptable method of&#xD;
             birth control from the start of screening until 30 days after the last study drug&#xD;
             administration. Oral contraceptives are prohibited&#xD;
&#xD;
          -  Agree not to ingest alcohol, drinks containing xanthine &gt;500 mg/day (e.g., Coca ColaÂ®,&#xD;
             coffee, tea, etc.), or grapefruit/grapefruit juice or participate in strenuous&#xD;
             exercise 72 hours prior to admission through the last blood draw of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contact site directly for more information&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Kelsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vince and Associates Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

